Rian Kabir, MD (@RianKMD) header
Rian Kabir, MD (@RianKMD) profile picture

Clinical AI @UpToDate. Metabolic Psychiatrist @EntheoClinic. Exploring the latent space between: design—medicine—technology—altered states of consciousness 🌌

Sacramento, CA
Joined December 2020
Photo by Rian Kabir, MD (@RianKMD)Photo by Rian Kabir, MD (@RianKMD)Photo by Rian Kabir, MD (@RianKMD)Photo by Rian Kabir, MD (@RianKMD)Photo by Rian Kabir, MD (@RianKMD)Photo by Rian Kabir, MD (@RianKMD)Photo by Rian Kabir, MD (@RianKMD)Photo by Rian Kabir, MD (@RianKMD)Photo by Rian Kabir, MD (@RianKMD)Photo by Rian Kabir, MD (@RianKMD)
“I would like my life to be a statement of love and compassion—and where it isn't, that's where my work lies.” — Ram Dass
7
26
151
26,877
Medicalization of psychedelics is only the first step towards creating a society and culture that can accept, hold, and integrate altered states of consciousness.
"I see the psychedelic experience as a birthright, and we can’t have a free society until people are free to explore their own mind." - Terrance McKenna
4
12
334
The DEA would make caffeine schedule I if it were discovered today.
if caffeine were discovered today it would be considered a strange scary underground research chemical with severe cardiac health risks until passing enough trials to become an overpriced, over restricted prescription drug for narcolepsy or something but since they discovered coffee before everything became gay and retarded you can just buy a redbull and it just works if you understand this you can understand why deranged "biohackers" love putting random "drugs" in their bodies we just use like to see if shit works, and use it if it works
15
102
7
1,478
26,567
There is a huge opportunity for hospitals to use psychedelics for those who are inpatient and severely ill Someone dying of cancer can’t go to a healing center or clinic The raises some questions about set & setting in a hospital…notoriously a bad setting for altered states
$CMPS $DFTX $HELP Hospital leaders are starting to talk more openly about psychedelics as a potential option for patients who have not responded to standard treatments. From Healthcare Brew: “Psychedelics news has been everywhere lately. Psilocybin (magic mushrooms) is being tested for treatment-resistant depression (TRD), LSD is being studied for generalized anxiety disorder, and MDMA is in clinical trials as a PTSD treatment. TRD patients are associated with more healthcare resource use and higher care costs. A 2021 retrospective study found that commercially insured patients with certain chronic pain conditions and a TRD diagnosis had higher healthcare use: an annual average of $6,300 more per patient a year compared to those with the same conditions who responded to treatments.” Joshua Eloge, associate director of the Women’s Board Depression Treatment Research Center at Rush University Medical Center, told the outlet it can be “frustrating and a bit demoralizing” for patients when typical treatments don’t work, and that there is “something really important about leading into a new phase of treatment and having that available to patients.” He also noted that hospitals able to offer these options can stand out as places providing cutting edge care. The patients who stand to benefit first from psychedelic therapies entering the market are those who have already tried and failed multiple standard treatments. That is true in TRD, and it is the expected early pathway for GAD and MDD as well. The resource and cost numbers cited in the article help explain why health systems are starting to take this seriously. Hospital leaders speaking about psychedelics as a practical option for non responders is a meaningful step beyond general research interest. healthcare-brew.com/stories/…
4
2
19
762
I will be doing a live Q&A about psychedelic medicine today on Spaces from 11:30a - 1p PT. Stop by if you’re curious about the science, safety considerations, and the deeper questions surrounding consciousness, mysticism, and personal transformation. teapawt.org/i/spaces/1AMPeeOZznEjM…

1
4
158
And audacity. With both, only the laws of physics limit you.
cleverness still commands a premium
4
256
I’m giving a talk on psychedelic medicine. This will be an in-depth discussion squaring the hope and the hype of these transformative tools. If you’re in the Sacramento area, here is the RSVP: luma.com/big-1032
2
4
8
536
I’m spending much of my time on music - therapeutic in altered states with or without psychoactive meds. Music influences both set and setting. It is core to guiding a chaotic trip towards healing and insight.
Healthy adults who took psilocybin in a calm room with music reported stronger mystical experiences than those dosed inside an MRI scanner. Their brain scans a week later also hinted at more synaptic change. dlvr.​it/TW9VRP
4
13
907
20 years ago, Roland Griffiths published the psilocybin study that helped usher in the psychedelic renaissance. When I was in med school, psychedelic medicine was fringe. Now it’s nearing FDA review. How far we’ve come. Wish Dr Griffiths were here to see it.
Nonprofit psychedelic research organisation Usona Institute has completed its submission of a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) concerning its psilocybin candidate for major depressive disorder (MDD), Psychedelic Alpha understands. It means it’s the second psychedelic NDA under review by the agency at present, after we reported that Resilient Pharmaceuticals (formerly Lykos Therapeutics) refiled its MDMA for PTSD application in the summer. It also means that FDA could hand down a decision on a psychedelic application in late 2026, if the most optimistic timelines hold, or very early in the new year, given the fact that Usona, like Compass Pathways, is in receipt of a Commissioner’s National Priority Voucher (CNPV) that aims to return a decision to a developer within two months. In our latest, we review the context surrounding Usona’s program and application, and what it might mean for its chief competitor, Compass, a for-profit psilocybin drug developer that is planning to submit its own NDA, for treatment-resistant depression (TRD), imminently. Read now on our website: psychedelicalpha.com/news/us…
2
1
22
986
Rian Kabir, MD retweeted
"And, regrettably, ours is a culture that is deeply suspicious of the unconscious, of mystery and the spiritual, and resentful of the time it takes for the intimate engagement required for such a therapy to work." - Psychiatrist Charles Savage's daughter, New Yorker, 2012.
2
7
326
Epistemic shock from 5-MeO-DMT is probably therapeutic if you’re severely depressed. Depression leads to such restrictive world + self models that a full re-set may be the most direct treatment.
5
3
2
61
7,009
It’s magical that anything exists at all.
1
7
302
The brain, constantly optimizing for survival and predictive accuracy, operates under a massive dimensionality problem. It compresses internal states and goals into low-dimensional narratives or symbols. These symbols are the archetypes Jung contemplated.
3
260
Being both a psychonaut and a psychiatrist has a lot of synergistic advantages.
3
15
631
One of my jobs is to work with consciousness. The other job is to work with AI. Its easy to think there is a ghost in the machine - the ghost being a symbolically oriented manifestation of the collective unconscious. Its qualia would be alien to ego-centric beings like us.
2
171
“Do they have any human-like properties of consciousness or cognition?” It has neither “human” nor “mouse” consciousness. The creature would instantiate a new phenotype of mind produced by a developmental history that has never existed evolutionarily. Neo-qualia.
An extraordinary @Nature paper has just landed from the lab of @Sergiu_P_Pasca at @Stanford - led by Konstantin Kaganovsky. They have found a way to create "xenocortical mice" which have ~92% of their cortex occupied by a cortical organoid derived from human stem cells. This human-derived cortical graft integrates deeply with the host nervous system, supporting organised neural activity and behaviour. This study is a milestone in synthetic biology and chimera research. It has the potential to generate multiple medical breakthroughs by providing an enhanced biological model of human brain tissue that allows behavioural as well as neural and genetic assays. The Stanford team have been exceptionally thorough and proactive in addressing ethical concerns that comes from this frontier work. But their pioneering work nonetheless raises many open questions: are the xenocortical mice conscious? Do they have any human-like properties of consciousness or cognition? @NitaFarahany and I will be addressing some of these questions in a forthcoming commentary - where we'll also offer an ethically-informed roadmap to guide this important research as it progresses. In this context, "pacing the frontier" really does make sense 😉 Read the Stanford @nature paper here, and buckle up. It's wild. nature.com/articles/s41586-0…
3
3
22
5,199
Medicine is more of a culture than it is in an exact science. It’s less like code and more like ritual. Core clinical reasoning task can be automated with current reasoning LLMs, but its implementation in patient care requires embodiment in relational fields.
1
1
7
285
We could have discovered this decades ago if psychedelics weren’t classified as schedule I due to the war on drugs. Just a reminder: the federal government still considers you a criminal for using these medicines. Change is happening, one step at a time.
Just two doses of psilocybin administered before chemotherapy completely prevented mice from developing neuropathy go.nature.com/4ibX56b
3
10
43
2,314
Patients with cluster headaches should be allowed to try DMT under compassionate use. It is one of the most painful and debilitating conditions a person can experience - many have found relief with DMT.
2
3
30
1,556
I believe the experience of the psychedelic trip itself is therapeutic. Reducing the time spent in a state of increased neural plasticity while simultaneously engaging with the content + insights that appears is short-sighted. Real transformation takes time and effort.
3
1
18
926
Building out my clinic’s infrastructure to deliver this to patients. Amazing that it will likely be possible in 2027…from prohibition to clinical trials and hopefully soon to FDA approvals 🤞🏽
2
1
1
18
1,621